• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Eli Lilly Invests Heavily in Debut Mounjaro TV Ad Campaign for Diabetes


Eli Lilly debuts its first Mounjaro TV commercial amid high demand for the diabetes injection, which also shows promise in weight loss applications and outperformed rivals Ozempic and Wegovy in clinical trials.

Eli Lilly has premiered its first Mounjaro TV commercial, 'What If?,' following a two-month shortage of the once-weekly diabetes injection.

Mounjaro (tirzepatide) is a first-in-class dual GLP-1 and GIP agonist that helps regulate blood sugar and appetite. GLP-1 receptor agonists like Mounjaro and Novo Nordisk's Ozempic have experienced shortages due to off-label prescriptions for obesity and weight loss.

Lilly spent $19.6 million on the ad, which highlights Mounjaro's ability to manage type 2 diabetes and decrease food intake. Mounjaro received FDA approval in May 2022 and has demonstrated superiority over Ozempic and Wegovy in head-to-head trials for fat mass reduction and A1C reduction targets. The FDA is expected to approve a weight loss version of Mounjaro later this year.

Reference: Eli Lilly Spends Big on First Mounjaro TV Commercial for Diabetes | April 6, 2023 | XTalks

Recent Videos
Related Content